Cryoport, Inc.
CYRX evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $862.0M
What it means
What to watch
Prepared research question
What matters most for CYRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYRX
Cryoport, Inc. (CYRX) is a temperature-controlled supply chain solutions provider for the life sciences industry, with a focus on supporting the clinical development and commercial launch of cell and gene therapies globally.
Key risk: Continued net losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$862.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Cryoport, Inc. (CYRX) is a temperature-controlled supply chain solutions provider for the life sciences industry, with a focus on supporting the clinical development and commercial launch of cell and gene therapies globally.
- Cash & equivalents of $269.3M as of 2026-06-30 [sec].
- Total revenue of $49.0M and net income of -$8.3M for the six months ended 2026-06-30 [sec].
- Supported 779 clinical trials, of which 94 were in Phase 3, and 22 commercial therapies as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Full-year 2025 revenue of $176.2 million, marking 12.4% year-over-year growth [sec · filed 2026-04-22].
- Forecasting 2026 revenue of $190 million to $194 million as of December 31, 2025 [sec · filed 2026-04-22].
What works
- Revenue growth: Full-year 2025 revenue increased 12.4% year-over-year to $176.2 million, exceeding guidance [sec · filed 2026-04-22].
- Strong pipeline of clinical trials and commercial therapies: Supported 779 clinical trials and 22 commercial therapies as of June 30, 2026, with a 14.8% year-over-year increase in CGT clinical trial revenue for the first half of 2026 [sec_mda · as of 2026-08-06].
- Return to EBITDA profitability in Q2 2026, with positive operating cash flow [news · published 2026-09-25].
- Established strategic relationship with DHL Group, expanding global supply chain network [sec · filed 2026-04-22].
What to weigh
- Net loss of -$8.3M for the six months ended June 30, 2026, indicating continued unprofitability [sec].
- Life Sciences Products revenue decreased by 0.4% in Q2 2026 compared to Q2 2025, showing uneven segment performance [sec_mda · as of 2026-08-06].
- Forward-looking statements caution that expectations about future business plans, regulatory approvals, and financial performance are based on assumptions and should not be unduly relied upon [sec · filed 2026-04-22].
- Total debt of $186.2M as of 2026-06-30, representing a significant liability [sec].
From the filings
Quoted directly from source documents.
Number of clinical trials and commercial therapies supported as of June 30, 2026
“As of June 30, 2026, we supported 779 clinical trials, of which 94 were in Phase 3, and 22 commercial therapies.”
SEC MD&A · August 6, 2026
Full-year 2025 revenue and growth rate
“We delivered full-year revenue of $176.2 million, exceeding the high end of our guidance and marking 12% year-over-year growth”
SEC filings · April 22, 2026
Return to EBITDA profitability in Q2 2026
“Cryoport returned to EBITDA profitability in 2Q26, with strong Life Science Services growth and positive operating cash flow.”
News · September 25, 2026
Risks & what to watch (4)›
Key risks
- Continued net losses — Net income of -$8.3M for the six months ended June 30, 2026, indicating ongoing unprofitability [sec].
- Debt burden — Total debt of $186.2M as of 2026-06-30, which may strain future cash flows [sec].
- Dependence on therapy approvals — Future revenue growth relies on anticipated new therapy approvals and BLA/MAA filings, which are uncertain [sec · filed 2026-04-22].
- Forward-looking statement risks — Management cautions that forward-looking statements about business plans and financial performance should not be unduly relied upon [sec · filed 2026-04-22].
What to watch
- Revenue performance against 2026 forecast of $190M–$194M [sec · filed 2026-04-22].
- Number of new therapy approvals and BLA/MAA filings in 2026, with nine new approvals anticipated [sec · filed 2026-04-22].
- Progress toward sustained profitability following return to EBITDA profitability in Q2 2026 [news · published 2026-09-25].
- Growth in commercial cell and gene therapy revenue, which increased 28.6% in 2025 [sec · filed 2026-04-22].
Sources: News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Cryoport, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cryoport, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.54 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Financials
Short Interest
as of May 20, 2026- % of float
- 5.3%
- Days to cover
- 5.0
- Shares short
- 2,202,556
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cryoport, Inc.?
Cryoport, Inc. (CYRX) is a temperature-controlled supply chain solutions provider for the life sciences industry, with a focus on supporting the clinical development and commercial launch of cell and gene therapies globally.
Who is the CEO of Cryoport, Inc.?
Mr. Jerrell W. Shelton is the chief executive officer of Cryoport, Inc. (CYRX).
Where is Cryoport, Inc. headquartered?
Cryoport, Inc. (CYRX) is headquartered in Brentwood, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.